Abstract 115P
Background
Immune checkpoint inhibitors (ICIs), a standard in the treatment of various cancer types, induce immune-related adverse events (irAEs) that can potentially impact any organ. This can lead to discontinuation of ICI therapy, immunosuppression, hospital admissions, and even long-term sequelae. This study assessed irAE incidence among German ICI therapy patients using a German payers’ database.
Methods
Patients aged ≥ 12 years with hepatic or hepatocellular cancer (HCC), non-small cell lung cancer (NSCLC), renal, urothelial, or skin cancer initiating ICI therapy from 2017-2020 were included. Claims were analyzed for irAE diagnoses (ICD-10 codes; International Statistical Classification of Diseases and Related Health Problems, 10th version) within half a year after treatment initiation and grouped by affected organ. Incident cases were defined as patients with irAE diagnoses and no pre-existing irAE diagnoses / autoimmune disease the year before. Number of patients hospitalized due to an irAE was analyzed.
Results
Of 5,805,407 enrollees, 307,141 had one of the defined cancer types, and 6,350 started ICI therapy. Of these, 4,237 (66.7%) were male, with a mean (SD) age of 66.8 (10.7) years. 75.5% of the cohort had NSCLC, 19.9% skin cancer, 19.7% HCC, 18.6% renal, 10.3% urothelial cancer (including double counts for multiple cancers). Every second patient (n=3,163, 49.8%) was hospitalized with an irAE diagnosis within half a year after treatment initiation. Of the study population, a total of 1,996 patients (31.4% [95% CI: 30.3 – 32.6%] had incident irAEs. The most common irAEs detected by this analysis were respiratory (n=744, 11.7% [11.0 – 12.5%] and gastroenterological ones (n=493, 7.8% [7.1 – 8.5%]). In patients with HCC, 33.9% (95% CI: 31.4% - 36.6%, n=424) experienced irAEs, while in those with skin cancer, the incidence was 30.0% (95% CI: 27.6% - 32.6%, n=380).
Conclusions
This German population-based analysis demonstrates that every second patient treated with ICI needed inpatient treatment due to irAE diagnosis within half a year after ICI start. The incidence of irAEs varied across different types of cancer. irAE should be assigned ICD-10 codes to improve the data quality.
Legal entity responsible for the study
The authors.
Funding
Mallinckrodt Pharmaceuticals.
Disclosure
L. Heinzerling: Other, Institutional, Advisory Role: Mallinckrodt Pharmaceuticals. T. Vogelmann: Financial Interests, Institutional, Advisory Role: Mallinckrodt Pharmaceuticals. I.T. Seemann, A. Ingram: Financial Interests, Personal, Full or part-time Employment: Mallinckrodt Pharmaceuticals. T. Schubert: Financial Interests, Institutional, Advisory Role: Mallinckrodt Pharmaceuticals.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract